Direct Editing of Immune Cells In Vivo: The Beginning of Next-Generation Precision Immunotherapy
Reprogramming Immune Cells, the Dawn of a New Challenge
Traditional cell therapies involve a complex workflow in which cells are manufactured in the laboratory and then reinfused into the patient. High costs, time requirements, and manufacturing infrastructure limitations have prevented many patients from receiving these therapies. Consequently, researchers have begun to explore methods for directly modifying immune cells within the body.
Nanocarriers and CRISPR, Acting On‑Site
The new delivery platform employs non‑viral nanoparticles to edit genes directly in T cells, NK cells, and bone‑marrow–derived cells. Real‑time administration of editing tools such as CRISPR instantly remodels the tumor microenvironment and amplifies antitumor responses. This approach eliminates the cumbersome ex vivo cell expansion step while maintaining high precision.
Safety Validation and Early Clinical Translation
The research team demonstrated precise control over the biodistribution and expression of delivered genes and proposed strategies to minimize immune reactions and tumorigenic risk. Several early‑phase clinical trials are currently underway, with adverse‑event management and long‑term efficacy monitoring identified as key priorities. Regulatory approval and manufacturing standardization will be essential for patient‑level implementation.
Future Significance and Outlook, a Paradigm Shift in Therapy
If in‑body gene editing becomes feasible, personalized immunotherapies can be delivered more quickly and affordably. This technology holds the potential to revolutionize treatment not only for cancer but also for autoimmune diseases and infectious disorders.
The clinical success of cell-based immunotherapies has revolutionized treatment of cancer and other diseases by enabling precise and durable tumor targeting. However, while traditional ex vivo engineering of immune cells has demonstrated promise, these approaches are constrained by logistical, economic, and manufacturing challenges that hinder broad clinical adoption. In vivo immune engineering, which directly reprograms immune cells within the patient's body, is emerging as an attractive alternative to overcome these limitations and directly reshape the tumor microenvironment (TME) in situ and restore antitumor immunity. This review surveys current approaches to overcoming them through in vivo delivery platforms and therapeutic constructs to achieve direct in vivo gene editing. We further discuss key safety and efficacy considerations, such as biodistribution, gene expression control, immunogenicity, and tumorigenicity. Finally, we examine early clinical efforts and translational hurdles in bringing in vivo immune engineering strategies to the bedside.
This research eliminates the complex production and storage steps required to reprogram immune cells ex vivo, enabling direct in‑body reprogramming. Consequently, treatment costs are reduced and accessibility increased, allowing a larger number of patients to benefit more rapidly.